1. Home
  2. CTMX vs SQNS Comparison

CTMX vs SQNS Comparison

Compare CTMX & SQNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTMX
  • SQNS
  • Stock Information
  • Founded
  • CTMX 2008
  • SQNS 2003
  • Country
  • CTMX United States
  • SQNS France
  • Employees
  • CTMX N/A
  • SQNS N/A
  • Industry
  • CTMX Biotechnology: Pharmaceutical Preparations
  • SQNS Semiconductors
  • Sector
  • CTMX Health Care
  • SQNS Technology
  • Exchange
  • CTMX Nasdaq
  • SQNS Nasdaq
  • Market Cap
  • CTMX 85.3M
  • SQNS 85.7M
  • IPO Year
  • CTMX 2015
  • SQNS 2011
  • Fundamental
  • Price
  • CTMX $0.84
  • SQNS $3.11
  • Analyst Decision
  • CTMX Buy
  • SQNS Strong Buy
  • Analyst Count
  • CTMX 6
  • SQNS 1
  • Target Price
  • CTMX $5.77
  • SQNS $7.50
  • AVG Volume (30 Days)
  • CTMX 847.0K
  • SQNS 107.6K
  • Earning Date
  • CTMX 03-10-2025
  • SQNS 02-11-2025
  • Dividend Yield
  • CTMX N/A
  • SQNS N/A
  • EPS Growth
  • CTMX N/A
  • SQNS N/A
  • EPS
  • CTMX 0.16
  • SQNS 1.65
  • Revenue
  • CTMX $126,617,000.00
  • SQNS $30,555,000.00
  • Revenue This Year
  • CTMX $22.55
  • SQNS $10.14
  • Revenue Next Year
  • CTMX N/A
  • SQNS $8.54
  • P/E Ratio
  • CTMX $5.20
  • SQNS $1.90
  • Revenue Growth
  • CTMX 33.66
  • SQNS N/A
  • 52 Week Low
  • CTMX $0.79
  • SQNS $0.85
  • 52 Week High
  • CTMX $5.85
  • SQNS $7.43
  • Technical
  • Relative Strength Index (RSI)
  • CTMX 45.15
  • SQNS 50.30
  • Support Level
  • CTMX $0.82
  • SQNS $3.00
  • Resistance Level
  • CTMX $0.98
  • SQNS $3.64
  • Average True Range (ATR)
  • CTMX 0.06
  • SQNS 0.22
  • MACD
  • CTMX 0.01
  • SQNS -0.01
  • Stochastic Oscillator
  • CTMX 33.58
  • SQNS 34.78

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About SQNS Sequans Communications S.A.

Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its solutions incorporate baseband processor and radio frequency, transceiver integrated circuits, along with its proprietary signal processing techniques, algorithms, and software stacks. The company's solutions serve as the core wireless broadband communications platform in devices, including smartphones, USB dongles, portable routers, laptops, netbooks, tablets, and other consumer multimedia and industrial devices. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.

Share on Social Networks: